Literature DB >> 12510056

Linezolid-induced lactic acidosis.

Aaron A Apodaca, Robert M Rakita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12510056     DOI： 10.1056/NEJM200301023480123

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  31 in total

1.  Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients.

Authors:  Emma Bishop; Sharmila Melvani; Benjamin P Howden; Patrick G P Charles; M Lindsay Grayson
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

2.  Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.

Authors:  N Duewelhenke; O Krut; P Eysel
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

3.  Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones.

Authors:  E E McKee; M Ferguson; A T Bentley; T A Marks
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  A case of lactic acidosis induced by linezolid.

Authors:  Juan Carlos Q Velez; Michael G Janech
Journal:  Nat Rev Nephrol       Date:  2010-04       Impact factor: 28.314

5.  Fatal lactic acidosis associated with linezolid therapy.

Authors:  M Djibré; T Pham; M Denis; V Pras Landre; M Fartoukh
Journal:  Infection       Date:  2014-10-19       Impact factor: 3.553

6.  Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia.

Authors:  Glòria Garrabou; Alejandro Soriano; Sònia López; Jordi P Guallar; Marta Giralt; Francesc Villarroya; Jose A Martínez; Jordi Casademont; Francesc Cardellach; Josep Mensa; Oscar Miró
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

7.  Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.

Authors:  Devyani Deshpande; Shashikant Srivastava; Eric Nuermberger; Thearith Koeuth; Katherine R Martin; Kayle N Cirrincione; Pooi S Lee; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

8.  Comparative analysis of lactic acidosis induced by linezolid and vancomycin therapy using cohort and case-control studies of incidence and associated risk factors.

Authors:  Nobuaki Mori; Yoshio Kamimura; Yuki Kimura; Shoko Hirose; Yasuko Aoki; Seiji Bito
Journal:  Eur J Clin Pharmacol       Date:  2017-12-08       Impact factor: 2.953

9.  Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.

Authors:  Shawn Flanagan; Edward E McKee; Debaditya Das; Paul M Tulkens; Hiromi Hosako; Jill Fiedler-Kelly; Julie Passarell; Ann Radovsky; Philippe Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

Review 10.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.